Ron Hunt

Ron Hunt

Managing Director, New York, NY

ron@nlvpartners.com
646-871-6400
Ron Hunt is a Managing Director at New Leaf Venture Partners, and focuses on early to late stage investments in biopharmaceuticals.  Ron was one of the founders of New Leaf in 2005, and today has over 2 decades of experience investing in and building companies focused on developing novel medicines that address important unmet medical needs.  Prior to his start in venture capital in 1998, Ron was a strategy and operations consultant to clients in the pharmaceutical and medical device industries. His experience also includes a number of sales and marketing positions with Johnson & Johnson and SmithKline Beecham Pharmaceuticals. Ron is a graduate of The Wharton School (M.B.A.) and Cornell University (B.S.).

Board Seats and Investments

Notable Alumni Investments

Aspreva Pharmaceuticals (NASDAQ: ASPV, Acquired by Galenica Group)
Cerexa (Acquired by Forest Laboratories)
Durata Therapeutics (NASDAQ: DRTX, Acquired by Actavis PLC)
Nycomed (Acquired by Takeda Pharmaceuticals)
Phase Forward (NASDAQ: PFWD, Acquired by Oracle)
Pathology Partners (Acquired by Caris Group)
Relypsa (NASDAQ: RLYP, Aquired by Vifor Pharma)
Stromedix (Acquired by Biogen Idec)